Roche to enter FGF21 space with $2.4B buyout of MASH biotech 89bionews2025-09-18T11:02:16+00:00September 18th, 2025|Endpoints News|
Joe Jimenez’s new biotech inks up to $1B biobuck deal for Mabwell’s cardio siRNAnews2025-09-17T13:32:58+00:00September 17th, 2025|Endpoints News|
CSL spends $117M to support development of VarmX’s blood clotting drugnews2025-09-16T10:42:02+00:00September 16th, 2025|Endpoints News|
GHO Capital buys Scientist.com, provider of a drug development marketplacenews2025-09-16T10:00:46+00:00September 16th, 2025|Endpoints News|
Updated: Novartis extends deal spree with $120M for Monte Rosa’s immune degradersnews2025-09-15T11:29:56+00:00September 15th, 2025|Endpoints News|
Novartis to spend $1.4B on Tourmaline Bio, gaining new heart drugnews2025-09-09T10:47:20+00:00September 9th, 2025|Endpoints News|
Servier buys Medicxi startup’s fragile X candidate for up to $450Mnews2025-09-08T06:30:05+00:00September 8th, 2025|Endpoints News|
Hengrui does another US deal, this time in Cytokinetics’ cardio arenanews2025-09-05T08:01:47+00:00September 5th, 2025|Endpoints News|
Remedy Meds buys virtual health startup Thirty Madison for $500Mnews2025-09-03T20:35:54+00:00September 3rd, 2025|Endpoints News|
Novartis signs one of the year’s largest biobuck deals with Shanghai biotech Argonews2025-09-03T14:55:31+00:00September 3rd, 2025|Endpoints News|
